Display options
Cite
Cain DJ, Del Arroyo AG, Ackland GL. Uncontrolled sepsis: a systematic review of translational immunology studies in intensive care medicine. Intensive Care Med Exp. 2014;2(1):6doi: 10.1186/2197-425X-2-6.
Cain, D. J., Del Arroyo, A. G., & Ackland, G. L. (2014). Uncontrolled sepsis: a systematic review of translational immunology studies in intensive care medicine. Intensive care medicine experimental, 2(1), 6. https://doi.org/10.1186/2197-425X-2-6
Cain, David J, et al. "Uncontrolled sepsis: a systematic review of translational immunology studies in intensive care medicine." Intensive care medicine experimental vol. 2,1 (2014): 6. doi: https://doi.org/10.1186/2197-425X-2-6
Cain DJ, Del Arroyo AG, Ackland GL. Uncontrolled sepsis: a systematic review of translational immunology studies in intensive care medicine. Intensive Care Med Exp. 2014 Dec;2(1):6. doi: 10.1186/2197-425X-2-6. Epub 2014 Feb 27. PMID: 26266907; PMCID: PMC4513024.
Copy Download .nbib Format: NLM
Share it on

Intensive Care Med Exp. 2014 Dec;2(1):6. doi: 10.1186/2197-425X-2-6. Epub 2014 Feb 27.

Uncontrolled sepsis: a systematic review of translational immunology studies in intensive care medicine.

Intensive care medicine experimental

David J Cain, Ana Gutierrez Del Arroyo, Gareth L Ackland

Affiliations

  1. Clinical Physiology, Wolfson Institute for Biomedical Research, Department of Medicine, University College London, London, WC1E 6BT, UK, [email protected].

PMID: 26266907 PMCID: PMC4513024 DOI: 10.1186/2197-425X-2-6

Abstract

BACKGROUND: The design of clinical immunology studies in sepsis presents several fundamental challenges to improving the translational understanding of pathologic mechanisms. We undertook a systematic review of bed-to-benchside studies to test the hypothesis that variable clinical design methodologies used to investigate immunologic function in sepsis contribute to apparently conflicting laboratory data, and identify potential alternatives that overcome various obstacles to improve experimental design.

METHODS: We performed a systematic review of the design methodology employed to study neutrophil function (respiratory burst), monocyte endotoxin tolerance and lymphocyte apoptosis in the intensive care setting, over the past 15 years. We specifically focussed on how control samples were defined, taking into account age, gender, ethnicity, concomitant therapies, timing of sample collection and the criteria used to diagnose sepsis.

RESULTS: We identified 57 eligible studies, the majority of which (74%) used case-control methodology. Healthy volunteers represented the control population selected in 83% of studies. Comprehensive demographic data on age, gender and ethnicity were provided in ≤48% of case control studies. Documentation of diseases associated with immunosuppression, malignancy and immunomodulatory therapies was rare. Less than half (44%) of studies undertook independent adjudication for the diagnosis of sepsis while 68% provided microbiological data. The timing of sample collection was defined by highly variable clinical criteria. By contrast, surgical studies avoided many such confounders, although only one study in surgical patients monitored the study group for development of sepsis.

CONCLUSIONS: We found several important and common limitations in the clinical design of translational immunologic studies in human sepsis. Major elective surgery overcame many of these methodological limitations. The failure of adequate clinical design in mechanistic studies may contribute to the lack of translational therapeutic progress in intensive care medicine.

References

  1. Arch Surg. 2000 Oct;135(10):1141-7 - PubMed
  2. BMC Immunol. 2010 Jan 25;11:4 - PubMed
  3. Crit Care Med. 1999 Nov;27(11):2459-68 - PubMed
  4. Clin Exp Immunol. 2011 Jun;164(3):346-56 - PubMed
  5. J Surg Res. 2000 Feb;88(2):200-6 - PubMed
  6. Intensive Care Med. 1998 Nov;24(11):1181-6 - PubMed
  7. Nature. 1993 Apr 29;362(6423):849-52 - PubMed
  8. J Immunol. 2001 Jun 1;166(11):6952-63 - PubMed
  9. Crit Care. 2013 Mar 18;17(2):R50 - PubMed
  10. Crit Care Med. 2003 Apr;31(4):1250-6 - PubMed
  11. Immunobiology. 2011 Mar;216(3):334-42 - PubMed
  12. Br J Anaesth. 2007 Feb;98(2):196-203 - PubMed
  13. Shock. 2007 Feb;27(2):151-6 - PubMed
  14. Crit Care. 2009;13(6):R172 - PubMed
  15. Clin Microbiol Rev. 2010 Jul;23(3):590-615 - PubMed
  16. Crit Care. 2010;14(6):R215 - PubMed
  17. Surg Infect (Larchmt). 2003 Summer;4(2):171-80 - PubMed
  18. Crit Care. 2008;12 (5):R128 - PubMed
  19. Langenbecks Arch Surg. 2009 Mar;394(2):293-302 - PubMed
  20. Crit Care Med. 2007 May;35(5):1244-50 - PubMed
  21. Front Cell Infect Microbiol. 2012 Feb 16;2:12 - PubMed
  22. Am J Ther. 2004 Sep-Oct;11(5):354-65 - PubMed
  23. Clin Exp Immunol. 1998 Apr;112(1):120-5 - PubMed
  24. J Trauma. 1999 May;46(5):774-81; discussion 781-3 - PubMed
  25. Crit Care. 2006;10(2):R42 - PubMed
  26. Clin Immunol. 2012 Oct;145(1):44-54 - PubMed
  27. J Clin Anesth. 2009 Sep;21(6):414-21 - PubMed
  28. Clin Exp Immunol. 2011 Oct;166(1):1-15 - PubMed
  29. Science. 2011 Mar 25;331(6024):1565-70 - PubMed
  30. Anesth Analg. 1998 Sep;87(3):695-700 - PubMed
  31. Shock. 2002 Dec;18(6):487-94 - PubMed
  32. Shock. 2003 Nov;20(5):415-9 - PubMed
  33. Crit Care Med. 1999 Jul;27(7):1230-51 - PubMed
  34. J Clin Invest. 2013 Mar;123(3):958-65 - PubMed
  35. Shock. 2003 Sep;20(3):208-12 - PubMed
  36. Shock. 2004 Nov;22(5):403-9 - PubMed
  37. Eur J Anaesthesiol. 2006 Nov;23(11):948-53 - PubMed
  38. J Trauma. 2001 Jul;51(1):92-7 - PubMed
  39. Cytokine. 2002 Mar 7;17(5):275-84 - PubMed
  40. Shock. 2000 Sep;14(3):271-6; discussion 276-7 - PubMed
  41. Am J Emerg Med. 1999 Jan;17(1):15-8 - PubMed
  42. N Engl J Med. 2012 May 31;366(22):2055-64 - PubMed
  43. J Trauma. 1974 Mar;14(3):187-96 - PubMed
  44. Ann Surg. 2000 Aug;232(2):208-15 - PubMed
  45. J Leukoc Biol. 2011 Mar;89(3):343-9 - PubMed
  46. Crit Care. 2011;15(2):R99 - PubMed
  47. J Immunol. 2008 May 1;180(9):6421-9 - PubMed
  48. N Engl J Med. 2009 Mar 26;360(13):1283-97 - PubMed
  49. JAMA. 2010 Jun 23;303(24):2495-503 - PubMed
  50. Infection. 2008 Oct;36(5):485-7 - PubMed
  51. J Biol Chem. 2011 Mar 18;286(11):9856-64 - PubMed
  52. J Am Coll Cardiol. 2009 Mar 24;53(12):1013-20 - PubMed
  53. Crit Care Med. 2001 Jan;29(1):129-33 - PubMed
  54. Chest. 1992 Jun;101(6):1644-55 - PubMed
  55. Crit Care. 2010;14(3):R96 - PubMed
  56. Eur J Surg. 1999 Nov;165(11):1020-3 - PubMed
  57. N Engl J Med. 2008 Jan 10;358(2):111-24 - PubMed
  58. Ann Surg. 2012 Dec;256(6):973-81 - PubMed
  59. J Immunol. 2004 Mar 1;172(5):2731-8 - PubMed
  60. Intensive Care Med. 2004 Jan;30(1):96-102 - PubMed
  61. J Innate Immun. 2010;2(5):461-8 - PubMed
  62. J Trauma. 1999 May;46(5):784-92; discussion 792-3 - PubMed
  63. Intensive Care Med. 2008 Jan;34(1):17-60 - PubMed
  64. J Exp Med. 2011 Dec 19;208(13):2581-90 - PubMed
  65. Chest. 1991 Dec;100(6):1619-36 - PubMed
  66. Crit Care Med. 2000 Sep;28(9):3207-17 - PubMed
  67. J Crit Care. 2012 Aug;27(4):384-93 - PubMed
  68. J Trauma. 2007 Apr;62(4):805-11 - PubMed
  69. Shock. 1999 Dec;12(6):421-7 - PubMed
  70. Kidney Int. 2001 Oct;60(4):1598-605 - PubMed
  71. Am Rev Respir Dis. 1989 Apr;139(4):1058-9 - PubMed
  72. Nature. 2010 Mar 4;464(7285):104-7 - PubMed
  73. Shock. 2012 Jul;38(1):18-23 - PubMed
  74. J Am Coll Surg. 2010 Dec;211(6):791-7 - PubMed
  75. J Trauma. 2009 Nov;67(5):968-74 - PubMed
  76. Crit Care. 2011 Jun 28;15(3):R158 - PubMed
  77. Arch Immunol Ther Exp (Warsz). 2011 Oct;59(5):385-97 - PubMed
  78. Crit Care. 2011;15(1):R70 - PubMed
  79. Biochem Biophys Res Commun. 2003 Sep 5;308(4):840-6 - PubMed
  80. Crit Care. 2010;14(4):R133 - PubMed
  81. Biochem Biophys Res Commun. 2003 Nov 14;311(2):465-72 - PubMed
  82. Anesth Analg. 2001 May;92(5):1322-6 - PubMed
  83. Surgery. 2001 Oct;130(4):669-75; discussion 675-6 - PubMed
  84. Crit Care Med. 1985 Oct;13(10):818-29 - PubMed

Publication Types